"The voice for cancer physicians and their patients in Massachusetts."

FDA approved atezolizumab (Tecentriq) for alveolar soft part sarcoma

12 Dec 2022 8:24 AM | Katy Monaco (Administrator)

Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). Read more.

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software